PET/MRI for Prostate Cancer

Phase-Based Progress Estimates
Prostate CancerPET/MRI - DiagnosticTest
What conditions do you have?

Study Summary

This trial is testing a new cancer-detecting tracer to see if it's more accurate than current imaging methods.

Eligible Conditions
  • Prostate Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
Side effects

Trial Safety

Trial Design

1 Treatment Group

Prostate cancer patients
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: PET/MRI · No Placebo Group · Phase 1

Prostate cancer patientsExperimental Group · 4 Interventions: PET/MRI, Blood and urine sampling, laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection, (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots · Intervention Types: DiagnosticTest, Other, Procedure, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,832 Previous Clinical Trials
584,528 Total Patients Enrolled
127 Trials studying Prostate Cancer
65,405 Patients Enrolled for Prostate Cancer
Elucida OncologyIndustry Sponsor
2 Previous Clinical Trials
187 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,085 Previous Clinical Trials
41,141,501 Total Patients Enrolled
536 Trials studying Prostate Cancer
502,384 Patients Enrolled for Prostate Cancer
Karim Touijer, MD, MPHPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Eligibility Criteria

Age 18+ · Male Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Physicians use their discretion to decide who is fit for surgery.
if tumor extends beyond prostate capsule The patient is scheduled for a laparoscopic radical prostatectomy, which is the standard of care
) Patients who have a suspicious-looking pelvic lymph node on either a CT or MRI scan, or who have a node that appears round, irregular, or lacking a fatty hilum on imaging, and who also have a high level of PSMA on a PSMA PET scan, may be candidates for treatment with Prostvac.
The patient has been scheduled to have the standard of care surgery to remove their pelvic lymph nodes
The tumor is at a clinical stage of T3a or higher.
The Gleason score is 8-10, or the PSA level is greater than 20 ng/mL.